We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




TAVR Reduces Heart Valve Replacement Mortality

By HospiMedica International staff writers
Posted on 22 Mar 2015
A new study confirms that elderly aortic stenosis patients once considered too frail or too sick for a standard valve replacement are living longer thanks to transcatheter aortic valve replacement (TAVR).

Researchers at the Cleveland Clinic (OH, USA), Emory University (Atlanta, GA, USA) and other institutions reported the five-year outcomes of the placement of aortic transcatheter valves (PARTNER) trial, part of which compared TAVR with surgical aortic valve replacement (SAVR) in high-risk patients with aortic stenosis. More...
The randomized controlled trial was held at 25 hospitals in Canada, Germany, and the USA, with the primary outcome being all-cause mortality in the intention-to-treat population.

The 358 study participants (mean age 83 years), were evenly assigned to TAVR or standard SAVR treatment. The results showed that those who underwent TAVR lived longer, with better symptom management, fewer hospital readmissions, and better functional status. At five years, 28.2% of the TAVR patients were still alive, compared to only 6.4% of those undergoing standard therapy. Echo cardiography at five years showed durable hemodynamic benefit after TAVR, with no evidence of structural valve deterioration. The study was published on March 15, 2015, in the Lancet.

“TAVR should be strongly considered for patients who are not surgical candidates for aortic valve replacement to improve their survival and functional status,” concluded lead author Prof. Samir Kapadia, MD, director of the cardiac catheterization laboratories at the Cleveland Clinic. “This trial is the first—and will probably be the only—randomized aortic stenosis trial that includes a group of patients not treated with aortic valve replacement, since these results will make it unethical to treat severe aortic stenosis patients with medical therapy alone.”

The percutaneous treatment of severe aortic valve disease (AVD) using a TAVR prosthetic aortic valve replacement, without the need for open heart surgery or cardiopulmonary bypass, is faster and less invasive than current open-heart procedures. TAVR has so far been proven effective in high-risk and inoperable patients, and could soon become the standard of care even in moderate and low surgical risk patients.

Related Links:

Cleveland Clinic
Emory University



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Critical Care Cart
Avalo
New
Enteral Feeding Pump
Instilar 1420
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: the deep tissue in vivo sound printing (DISP) platform, which combines ultrasound with low-temperature–sensitive liposomes loaded with crosslinking agents (Photo courtesy of Elham Davoodi and Wei Gao/Caltech)

New Ultrasound-Guided 3D Printing Technique to Help Fabricate Medical Implants

3D bioprinting technologies hold considerable promise for advancing modern medicine by enabling the production of customized implants, intricate medical devices, and engineered tissues designed to meet... Read more

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.